MICRO PLUS 4 REGULAR STRENGTH LIQUID

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CHROMIUM (CHROMIC CHLORIDE); ZINC (ZINC SULFATE); COPPER (CUPRIC SULFATE); MANGANESE (MANGANESE SULFATE)

Pieejams no:

SANDOZ CANADA INCORPORATED

ATĶ kods:

B05XA31

SNN (starptautisko nepatentēto nosaukumu):

ELECTROLYTES IN COMB WITH OTHER DRUGS

Deva:

4MCG; 1MG; .4MG; .1MG

Zāļu forma:

LIQUID

Kompozīcija:

CHROMIUM (CHROMIC CHLORIDE) 4MCG; ZINC (ZINC SULFATE) 1MG; COPPER (CUPRIC SULFATE) .4MG; MANGANESE (MANGANESE SULFATE) .1MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

10X5ML VIAL

Receptes veids:

Ethical

Ārstniecības joma:

REPLACEMENT PREPARATIONS

Produktu pārskats:

Active ingredient group (AIG) number: 0414689003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2006-06-07

Produkta apraksts

_MICRO +4 REGULAR STRENGTH (4 Trace Elements Injection USP) _
_Page 1 of 17 _
_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MICRO +4 REGULAR STRENGTH
4 Trace Elements Injection
Zinc, 1 mg/mL
Copper, 0.4 mg/mL
Manganese, 0.1 mg/mL
Chromium, 4 mcg/mL
USP
Intravenous
Combination of Electrolytes
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, (Québec), Canada
J4B 1K6
Date of Preparation:
APR 25, 1994
Date of Revision:
JAN 19, 2022
Control No.: 250301
_MICRO +4 REGULAR STRENGTH (4 Trace Elements Injection USP) _
_Page 2 of 17 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment (Pediatrics)
01/2022
7 WARNINGS AND PRECAUTIONS, General
01/2022
TABLE OF CONTENTS
Sections and Subsections that are not applicable at the time of
authorization are not listed.
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS.....................................................................................................................
4
1.1
P
EDIATRICS
(
≤
18 YEARS OF AGE
)
.....................................................................................
4
1.2
G
ERIATRICS
(≥
65 YEARS OF AGE
)
.....................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
4
4
DOSAGE AND
ADMINISTRATION........................................................................................
4
4.1
D
OSING
C
ONSIDERATIONS .....................................................................................................
4
4.2
R
ECOMMENDED
D
OSE AND
D
OSAGE
A
DJUSTMENT ......................................................................
5
4.3
R
ECONSTITUTION .................................................................................................................
6
4.4
A
DMINISTRATION ................................................................